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This study assesses the compliance of South African JSE-listed companies holding 
biological assets with the disclosure requirements of IFRS 13, Fair Value 
Measurement. The financial statements of nineteen selected JSE-listed companies 
with material holdings of biological assets were analysed. These financial statements 
were for the first reporting periods beginning on or after 1 January 2015, because IFRS 
13 was applicable to reporting periods from 1 January 2013 and the amendments to 
IAS 41 relating to bearer biological assets are applicable to reporting periods from 1 
January 2016. This research therefore examines the period between when IFRS 13 
first became applicable and before the IAS 41 amendments became applicable. The 
accounting policy notes to the financial statements of each company were analysed 
to determine whether they indicated that a particular company had applied IFRS 13 to 
the valuation of its biological assets, and the biological assets note was analysed to 
determine whether the valuation technique used by each company for the valuation of 
its biological assets complied with IFRS 13. The IFRS 13 level 3 disclosure 
requirements were listed and checked against each set of annual financial statements 
in order to assess the extent of their compliance with these disclosure requirements. 
The biological assets of the companies whose financial statements were analysed 
were categorised into bearer plants, consumable plants, bearer livestock, and 
consumable livestock. It was found that all companies but one stated that they had 
applied IFRS 13, and that all companies used level 3 inputs to value their biological 
assets. In terms of the valuation methods used, the results indicate that, while most 
companies favoured a cost approach for their bearer plants and an income approach 
for their consumable plants, the market approach was used most consistently for both 
bearer and consumable livestock. The results of the analysis of the disclosure 
revealed that, while all of the companies with consumable plants had complied with 
60% or more of the compulsory disclosures and 80% of the companies with bearer 
plants had complied with 50% or more of the disclosures, none of these companies 
had recorded realised and unrealised gains or losses separately and only one 
company with both bearer and consumable plants had provided a detailed description 
of the valuation process used. Similarly 78% of companies with bearer livestock and 
88% of companies with consumable livestock had complied with 60% or more of the 
compulsory disclosures and only one company with both bearer and consumable 
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livestock had complied with all ten disclosures. This study concludes that, while most 
JSE-listed companies with biological assets have gone to great lengths since January 
2013 when the application of IFRS 13 became mandatory, only one of the nineteen 
companies whose financial statements were analysed was fully compliant with IFRS 
13.  Further research may be able to identify the reasons why the remaining eighteen 
companies are not yet fully compliant with IFRS 13 in relation to their holdings of 
biological assets. This study contributes to the existing body of research on the 
financial reporting of entities with biological assets and agricultural produce in South 
Africa. While the agricultural sector is not as big as it used to be, it is still a significant 
contributor to the South African economy and improved compliance will result in 
increased comparability both within the agricultural sector as well as with other 
sectors. 
 
Key words: Agriculture, biological assets, fair value, IAS 41, IFRS 13. 
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1.1  Background 
In May 2011 the International Accounting Standard Board (IASB) issued International 
Financial Reporting Standard 13 (IFRS 13), Fair Value Measurement. IFRS 13 
provides guidance on how to determine the fair value of assets and liabilities by relying 
firstly on observable inputs and if observable inputs are not available, unobservable 
inputs are used (IASB, 2011). IFRS 13 is applicable in all situations where a specific 
International Accounting Standard (IAS) or an International Financial Reporting 
Standard (IFRS) requires an entity to measure assets or liabilities at fair value (IASB, 
2011). Among others, IFRS 13 is applicable to entities that are required to apply IAS 
41, Agriculture, to the fair value measurement of their agricultural activity. 
Agriculture is the foundation of developing economies. As one of 
these economies, South Africa needs to ensure a healthy agricultural industry that 
contributes to the country's gross domestic product (GDP), food security, social 
welfare, job creation and ecotourism, while adding value to raw materials (Goldblatt, 
2010). The sector’s contribution to the economy can be evaluated according to five 
main themes: the role of the sector as provider of food, earner of foreign exchange, 
employment provider, source of capital and buyer of goods or provider of inputs to the 
manufacturing sector (Greyling, 2015). The agricultural sector represented 
approximately 10% of the economy in 1960 and it currently represents less than 2,5%, 
this is low considering that it uses more than 80% of available land and around 60% 
of available water (Greyling, 2015). 
IAS 41 was issued by the International Accounting Standards Committee in February 
2001 and was adopted by the IASB in April 2001 (IASB, 2001). IAS 41 provides 
guidance on how to account for, present and disclose agricultural activity for the 
purpose of financial reporting (IASB, 2001). Agricultural activity relates to the 
management by an entity of the biological transformation and harvest of biological 
assets for sale or for conversion into agricultural produce or into additional biological 
assets (IASB, 2001, par 5). 
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IAS 41 requires entities to measure biological assets at initial and subsequent 
recognition, and agricultural produce at point of harvest, at fair value less costs to sell. 
When IAS 41 was issued it contained guidance on how the fair value of biological 
assets should be determined. IAS 41 encourages entities to use prices from active 
markets, if they exist, to measure their fair value. For cases where market prices are 
not available, the use of the most recent market prices, market prices for similar items 
or sector benchmarks are recommended. Fair value movements are required to be 
accounted for in profit or loss. From 1 January 2013 the fair value requirements 
contained in IFRS 13 have replaced those in IAS 41. 
IFRS 13 encourages entities to maximise the use of observable and relevant inputs 
from the market and minimise the use of unobservable inputs. It does this by creating 
a hierarchy of fair value inputs with three distinct levels. level 1 gives highest priority 
to unadjusted, quoted market prices for identical assets, level 2 inputs reflect prices 
for similar assets observable from the market, and level 3 inputs are unobservable 
inputs (IASB, 2011).  
IFRS 13 recommends that entities use any of the three different valuation techniques, 
namely the market approach, which is more aligned with levels 1 and 2, and the cost 
and income approaches, which are both more aligned with level 3.  
IFRS 13 and IAS 41 are not the only IASB standards affecting entities in the 
agricultural sector. In June 2014 the IASB issued a paper entitled “Agriculture: Bearer 
Plants” as an amendment to IAS 16, Property, Plant and Equipment (IASB, 2003) and 
IAS 41 (IASB, 2014). The amendment is intended to remove bearer plants from the 
scope of IAS 41 and place them within the scope of IAS 16 (IASB, 2014). Companies 
are required to apply these amendments to their financial statements for financial 
periods beginning on or after 1 January 2016 (IASB, 2014). 
 
1.2  Research problem  
Previous studies have focused on the compliance of entities holding biological assets 
with the disclosure requirement of IAS 41 in various countries. Studies were conducted 
in France by Elad and Herbohn (2011), in the United Kingdom by Butler (2001), in 
Spain by Argilés, García-Blandon and Monllau (2011), in New Zealand by Fisher, 
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Mortensen and Webber (2010), and in South Africa by Baigrie and Coetsee (2016). 
Yet to date no studies have looked at the compliance of companies holding biological 
assets with the disclosure requirements of IFRS 13. This is therefore the research 
problem that this dissertation will attempt to address. 
 
1.3  Research objectives 
Following on from the research problem discussed above, the research question that 
arises relates to the extent to which South African JSE-listed companies with material 
holdings of biological assets are applying IFRS 13 to the measurement and disclosure 
of these assets in their annual financial statements. The research question therefore 
is: “To what extent are South African public companies with material holdings of 
biological assets complying with the valuation and disclosure requirements of IFRS 13 
in relation to these assets?” This leads us to the aim of this research, which is to 
provide evidence of whether and how the South African JSE-listed companies 
selected for this research have managed to comply with the fair value guidance 
provided in IFRS 13, specifically in relation to the valuation, measurement and 
disclosure of their biological assets. 
To address this research question and the aim thereof, the following analyses were 
undertaken: 
 an analysis of the annual financial statements of these companies to identify 
whether or not they have indicated that they have applied IFRS 13 to their 
biological assets; 
 an analysis of the valuation techniques used by these companies for the 
recognition and measurement of these biological assets; and 
 an analysis of their compliance with the disclosure requirements of IFRS 13 
applicable to the level at which their biological assets were classified. 
 
1.4  Research methodology 
The methodology used to address the objectives of this study is a content analysis of 
the annual financial statements of the nineteen JSE-listed companies selected for 
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study. For the purposes of producing detailed results, the analysis divides the 
biological assets of these companies into four discrete categories, namely bearer 
plants, consumable plants, bearer livestock, and consumable livestock.  
The content analysis is done in four phases, the first being to determine whether each 
company has indicated compliance with IFRS 13 in relation to their biological assets, 
the second being to determine the valuation technique used by the company to value 
these assets, the third being to identify the level at which each company has classified 
their various holdings of biological assets, and the last being an analysis of their 
compliance with the disclosure requirements of IFRS 13 applicable to the level at 
which they have classified their various holdings of biological assets. 
 
1.5  Motivation 
Research on the financial reporting of companies with biological assets and holding of 
agricultural produce has increased in recent years. In South Africa, a number of 
studies have been conducted in recent years on the financial reporting of companies 
in the agricultural industry, such as those of Baigrie and Coetsee (2016), Philander 
(2016) and Van Biljon (2016). 
IAS 41 requires companies to measure their biological assets at fair value less cost to 
sell both at initial recognition and for subsequent measurement. IFRS 13 provides 
guidance on how to measure fair value and what needs to be disclosed in the financial 
statements for assets measured at fair value.  
Prior to the issuing of IFRS 13, studies were conducted on the advantages and 
disadvantages of measuring biological assets at fair value, as required by IAS 41. One 
of the advantages mentioned by Lefter and Roman (2007) is that recognising fair value 
movements in profit or loss can be of great relevance to the user’s decision-making 
process. Elad and Herbohn (2011) found that the disadvantage that was mentioned 
by auditors and accountants was the increased volatility of earnings if fair value 
accounting is applied to the measurement of biological assets. 
Some writers such as Elad (2004) looked at the cost versus benefit of valuing biological 
assets at fair value. Elad (2004) raised that there could excessive cost incurred in 
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trying to obtain the fair value while historical cost could easy be obtained.  
Nevertheless, the problem of comparability persisted due to the fact that IAS 41 
contained so many alternative valuation options for the measurement of the fair value 
of biological assets and agricultural produce at point of harvest. IFRS 13 aims to 
provide users with greater consistency – and therefore comparability – in relation to 
the fair-value measurement of various assets, including biological assets.  
 
1.6  Limitations 
This study is limited to companies listed on the JSE. There are more companies with 
material holdings of biological assets that are not listed on the JSE, but are still 
required by the Companies Act (South Africa, 2008) to prepare financial statements 
according to IFRS requirements. Due to time constraints, those companies do not form 
part of this research, because their annual financial statements are either not easily 
accessible or unavailable. 
This dissertation looks at financial statements prior to the June 2014 amendments to 
IAS 41, which require bearer plant holdings to be accounted for according to IAS 16. 
It therefore does not take these amendments into account.  
 
1.7  Ethical considerations 
This research analyses the annual financial statements of public companies that are 
listed on the JSE. It therefore relies solely on secondary data. Although the research 
involves neither humans nor any form of primary data, ethical clearance has been 
obtained from the University of Johannesburg’s School of Accounting’s Research and 
Ethics Committee. 
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1.8  Chapter layout 
The rest of the chapters of this dissertation are structured as follows: 
Chapter 2 – Literature review 
This chapter will look at recent academic journal articles dealing with accounting for 
biological assets. It looks specifically at the themes of relevance and faithful 
representation as they relate to biological assets, which are the two fundamental 
qualitative characteristics of useful financial information according to the Conceptual 
Framework (IASB, 2018: para. 2.5). 
Chapter 3 – Research methodology 
This chapter will explain the methods that were used in this research and the process 
used to select the financial statements of the companies that were studied. Detail is 
provided of the various steps taken in the research process. The IFRS 13 disclosure 
requirements are tabled, as well as the processes followed to test the compliance of 
the selected financial statements with these requirements. 
Chapter 4 – Results and discussion 
In this chapter the results of the research conducted are presented. Firstly, the results 
of the analysis of the application of IFRS 13 and the valuation techniques used by the 
selected companies are discussed, followed by a discussion of the extent of their 
compliance with the IFRS 13 disclosure requirements.  
Chapter 5 – Conclusion 
This chapter provides a summary of the research and the conclusions drawn from it. 
Areas for further research are also discussed. 
  





2.1  Introduction 
There has been a great deal of international research on financial reporting by entities 
engaged in agricultural activities in various part of the world, but since the introduction 
of IFRS 13 in January 2013 there has not been much research on how this standard 
impacts on entities with biological asset holdings. This study focuses specifically on 
the extent of compliance by selected South African JSE-listed companies holding 
biological assets with the disclosure requirements of IFRS 13. 
This chapter looks at prior research relating to the financial reporting of the fair value 
of biological assets. The objective of financial reporting is to provide the users of an 
entity’s annual financial statements with useful financial information about the entity 
(IASB, 2018: para. 1.2). The Conceptual Framework states that “If financial information 
is to be useful, it must be relevant and faithfully represent what it purports to represent. 
The usefulness of financial information is enhanced if it is comparable, verifiable, 
timely and understandable” (IASB, 2018: para. 2.4). The objectives of the Conceptual 
Framework apply to all the accounting standards, including IFRS 13 and IAS 41.  
According to the Conceptual Framework, therefore, relevance and faithful 
representation are the two fundamental qualitative characteristics of useful financial 
information. This research looks at the compliance by entities holding biological assets 
with the disclosure requirements of IFRS 13 as an indication of the increased 
standardisation and comparability of and, by extension, increased usefulness of the 
financial statements of agricultural entities.  
IFRS 13 encourages the use of observable inputs and discourages the use of 
unobservable inputs with the aim of reducing fair value measurement variability and 
subjectivity (IASB, 2013: para. IN10). Baigrie and Coetsee (2016) raise the question 
of whether IFRS 13 will achieve the objective of reducing subjectivity in fair value 
measurement by improving comparability among financial statements. This chapter 
looks at the extent to which the existing literature on the fair value reporting of 
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biological assets addresses these fundamental qualitative characteristics, as well as 
whether researchers believe that the introduction of IFRS 13 will improve the 
comparability and standardisation of financial information. 
 
2.2  Relevance of fair value reporting of biological assets  
Financial information is relevant when it can be used to predict future outcomes and 
when it gives feedback to users about previous evaluations (IASB, 2018: paras. 2.6-
2.9). Relevant information is also determined by how material a particular piece of 
information is to those using it. If misstating or omitting this information will have an 
impact on the decisions that will be taken by its users regarding the reporting entity, 
that information is material and therefore also relevant (IASB, 2018: para. 2.11). 
Goncalves and Lopes (2015), in their study evaluating the measurement practices of 
324 listed firms holding biological assets worldwide, find that most firms are using 
historical cost to account for these assets, because they believe that this is the best 
way to measure them. Furthermore, they find that companies need to consider many 
factors when valuing their biological assets, because these factors have a significant 
impact on the assets’ fair values. These factors are firm-level drivers, biological asset 
intensity and potential growth, firm size, listing status, regulation expertise, and 
industry sector. 
Argilés-Bosch, Miarons, García-Blandon, Benavente and Ravenda (2018), in their 
empirical analysis of the relevance of accounting information when biological assets 
are measured at fair value as compared to historical cost, find that the fair value 
valuation of biological assets is more reliable when predicting future cash flows. This 
is because the proportion of biological assets to total assets increases compared to 
historical cost valuations. However, they find that this does not apply to bearer plant 
holdings. 
 
In another study by Goncalves and Lopes (2015), they find that, in general, there is 
value relevance when firms measure their biological assets at fair value and exhibit 
high disclosure levels. They further state that, for consumable biological assets, it is 
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easy to find value in the market, so there is no need for companies to disclose a great 
deal of information about consumable biological assets. But, with bearer biological 
assets, investors really rely on information that firms disclose, hence the value 
relevance of higher levels of disclosure. 
In line with Goncalves and Lopes (2015), Da Silva, Rezende and Braunbeck (2016) 
conducted an experiment with market professionals from the executive MBA and 
students from the graduation course in accounting at the University of São Paulo in 
Brazil. They conclude that the use of the fair value measurement of biological assets 
is more relevant than historical cost. They also point out that reliability is still a concern 
because of the different approaches used to determine the fair value of assets when 
there is no active market. 
 
2.3  Faithful representation of biological assets  
The usefulness of financial information is enhanced by its faithful representation. To 
satisfy the qualitative characteristic of faithful representation, information needs to be 
complete, neutral and free from error (IASB, 2018: para. 2.13). Elad (2004) states that 
the value of biological transformation is better reflected when net market value is used, 
which faithfully represents a biological asset’s future economic benefits. 
It is worth mentioning that Abdullatif (2016), who researched the issues faced by 
external auditors in Jordan, finds that auditors were concerned that companies took 
advantage of fair value estimates to overvalue their assets, which would make fair 
value information less reliable.  
Filip, Hammami, Huang, Jeny, Magnan and Moldovan (2017), in their literature review 
analysis after the application of IFRS 13, conclude that: 
 the application of the IFRS 13 fair value hierarchy will benefit capital market 
participants (investors and analysts);  
 the fair value hierarchy is not sufficiently stable at levels 2 and 3; and 
 the use of level 3 allows managers to manipulate financial information. 
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The Conceptual Framework states that “although a single economic phenomenon can 
be faithfully represented in multiple ways, permitting alternative accounting methods 
for the same economic phenomenon diminishes comparability” (IASB, 2018: para. 
2.29). One of the main reasons for the introduction of IFRS 13 in 2013 was to increase 
comparability through greater consistency in fair value measurement and disclosure 
(IASB, 2013). 
 
2.4  Comparability of financial statements  
The IASB states that information reported in financial statements “is more useful if it 
can be compared with similar information about other entities and with similar 
information about the same entity for another period or another date” (IASB 2018: 
para. 2.24). Baigrie and Coetsee (2016) state that if entities with similar assets, 
liabilities and income sources are comparable, comparability is achieved. Nobes 
(2006) finds that the fact that a number of accounting standards allow for a choice 
between the use of a benchmark treatment or alternative measurement methods has 
resulted in a significant reduction in comparability, even among entities in the same 
sector.  
Elad and Herbohn (2011) state that IAS 41, instead of enhancing comparability and 
changing accounting practices, created an illusion of comparability. This is because, 
prior to the implementation of IFRS 13, IAS 41 provided too many alternative valuation 
methods and allowed for too much estimation by management. These authors 
conclude that it is almost impossible for the application of IAS 41 to improve 
comparability unless entities within the same industry agree to use similar valuation 
methods. The research conducted as part of this dissertation seeks to assess the 
extent to which the application of IFRS 13 addresses this problem. 
Comparability is compromised by allowing different accounting methods to be used by 
entities in the same industry (IASB, 2018: paras. 2.26-2.27). Van Biljon (2016) states 
that the use of IAS 41 on its own leads to financial statements that cannot be usefully 
compared, because the standard does not have a detailed valuation method. Van 
Biljon (2016) also states that because a number of alternative valuation methods are 
permitted in IAS 41, comparability will be directly affected by which method a particular 
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entity uses. She highlights the fact that the valuation methods in IAS 41 allow for the 
extensive use of estimates, and that this will impact on the credibility of the information 
produced, because inconsistences in estimates among entities will also impair 
comparability. 
The consensus to date seems to be that IAS 41 has completely failed to enhance 
comparability among agricultural entities. While Baigrie and Coetsee (2016) suggest 
that entities in the same economic sectors need to agree to apply similar valuation 
methods for biological assets if they want to increase comparability, it remains to be 
seen whether the introduction of IFRS 13 and its application to agricultural entities 
have resolved this problem.  
Philander (2016: 16) argues that “usefulness can be measured as the degree or extent 
to which financial information provides a sound basis to make informed decisions”. A 
greater emphasis on the standardisation of disclosure should lead to the increased 
usefulness of financial information.  
 
2.5  Standardisation of disclosure  
The aim of standardised disclosure is to make financial statements more easily 
understandable by diverse users across the globe. An increase in the standardisation 
of disclosure requirements will make it easier for users to know what to expect and 
how to read and interpret the financial information of any entity, which in turn will 
enable them to make more informed decisions about an entity whose financial 
information they are examining. 
While IFRS 13 and IAS 41 have encouraged entities to disclose more information 
about their biological assets, Goncalves and Lopes (2015) state that additional 
disclosure on consumable biological assets has no value relevance, which means that 
the additional disclosure in this context is unnecessary. Hou (2015), on the other hand, 
suggests that the standardisation of disclosure of forest assets enhances the value of 
the disclosure and provides more technical information, which will in turn improve 
comparability. 
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Van Biljon (2016) states that most organisations face challenges such as the cost of 
obtaining valuations, a lack of understanding of the valuation model, and issues 
relating to the measuring of the age and condition of plants and bearer livestock. She 
further states that most companies struggle with the valuation of biological assets 
because they only perform such a valuation once a year. She suggests that if 
valuations were done more frequently, it would enhance the skills and experience 
required to perform these valuations, which would in turn make fair value reporting 
more accurate and less burdensome. 
A correlation between compliance with IFRS 13, on the one hand, and the size of the 
both the firm and its auditors, on the other hand, was also identified. 
This research confirmed the earlier findings of Clavano (2014) who states that, while 
there is a positive correlation between firm size and the valuation methods used, it is 
the perceived importance of any required disclosure by the audit firm that determines 
whether or not the disclosure is included in the entity’s financial statements.  
These findings are also consistent with those by Baigrie and Coetsee (2016), who 
found greater consistency in disclosure between companies in the same industry 
sector. This concludes that standardisation of disclosure is intended to improve the 
comparability of financial statements of different entities, and that “the hope is that the 
inclusion of more extensive compulsory disclosures in the accounting standards will 
lead to greater standardisation of disclosure and therefore to greater comparability 
within economic sectors and across economic regions” (Baigrie & Coetsee, 2016: 
835). 
 
2.6  Conclusion 
The conceptual framework seeks to achieve that users of financial information have 
more confidence in the information, which will be achieved if the information is relevant 
and faithfully reported. It believed that, if so, it will improve capital markets’ functioning, 
which in turn will lead to a decrease in the cost of capital for the entire economy (IASB, 
2018: para. 2.41). It is hoped that the introduction of IFRS 13, through increased 
comparability of disclosure and more accurate use of fair value in financial statements, 
will enhance the qualitative characteristics of relevance and faithful representation. 
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In relation to biological assets, companies should ensure that they consider all factors 
affecting the biological asset in question in determining its fair value. Increased 
disclosure relating to the valuation methods used will achieve value relevance for 
many different types of biological assets, particularly those like forests and plantations, 
which require several inputs in order to arrive at a fair value. Companies with biological 
assets will need to achieve a balance between over-disclosure and under-disclosure. 
This can be done by disclosing more technical information about biological assets 
when market values are not available. The increased frequency of valuation 
calculations should also make it easier for companies to produce standardised 
information that is both relevant and faithfully represented. 
Faithful representation is enhanced when financial information is comparable and 
disclosed in a standardised way. Prior to the implementation of IFRS 13, IAS 41 made 
it difficult to compare financial information across entities, because it allowed for the 
use of many different valuation methods (Baigrie & Coetsee, 2016). It is hoped that 
IFRS 13, with its increased emphasis on the use of market-based valuations combined 
with greater disclosure requirements when other valuation methods are used, will lead 
to an increase in the standardisation of disclosure. However, there is a concern that 
disclosing too much information will not always be value relevant and it is hoped that 
standardised disclosure can be achieved through the use of minimal but relevant 
information.  
  





3.1  Introduction  
The research that forms part of this study involved a content analysis of the financial 
statements of South African JSE listed companies holding biological assets in their 
statements of financial position. In terms of IAS 41, entities with biological assets are 
required to measure these assets at fair value at the end of every reporting period. 
Previous research (Baigrie & Coetsee, 2016) looked at the compliance of South 
African companies with material holdings of biological assets with the disclosure 
requirement of IAS 41. Subsequent to this research, the IASB issued IFRS 13 Fair 
Value Measurement, which requires entities that hold assets and liabilities which must 
be carried at fair value to apply the valuation and additional disclosure requirements 
of this standard (IASB, 2011). This study looks at the compliance of JSE listed 
companies with holding biological assets with the disclosure requirements of IFRS 13. 
 
3.2  Research methodology 
As indicated in Chapter 1, the methodology used in this study is a content analysis of 
the annual financial statements of the nineteen JSE-listed companies selected for 
study. Krippendorff (2004) states that the term “content analysis” first appeared in 
Webster’s Dictionary of the English Language in 1961, when it was described as 
“analysis of the manifest and latent content of a body of communicated material 
through classification, tabulation and evaluation of its key symbols and themes in order 
to ascertain its meaning and probable effect” (Krippendorff, 2004: xvii).  
Shaw (2006) indicates that, while significant disagreement exists among researchers 
as to what constitutes “content analysis”, examples of content analysis “can involve 
the use of numbers to quantify some aspect of text” (Shaw, 2006: 3). Krippendorff 
describes content analysis as an “empirically grounded method” used to examine data 
or printed matter, among other sources, in order to understand their meaning as well 
as what they enable or prevent” (Krippendorff, 2004: xviii). While he questions the 
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usefulness of the distinction between qualitative and quantitative research, he qualifies 
this by stating that “all reading of texts is qualitative, even when certain characteristics 
of a text are later converted into numbers” (Krippendorff, 2004: 16). Shaw too refers 
to the distinction between qualitative and quantitative research as problematic and 
suggests that “Conceiving of different tendencies between closely related methods as 
cultural preferences rather than absolute distinctions helps us to reinterpret text 
analysis methods as a set of practices selected from a continuum of ‘quantitative’ and 
‘qualitative’ practices.” (Shaw, 2006: 6).  
Content analysis as a methodology varies from a simple quantification of text to 
complex analysis of text involving highly specialised procedures, facilitated by the use 
of computer coding and specialised software packages used to analyse the data. As 
the research that forms part of this study is exploratory in nature, a simple content 
analysis was considered to be the most appropriate methodology to use. 
The analysis divides the biological assets of the selected companies into four discrete 
categories, namely bearer plants, consumable plants, bearer livestock, and 
consumable livestock. The content analysis is done in four phases, the first being to 
determine whether each company has indicated compliance with IFRS 13 in relation 
to their biological assets, the second being to determine the valuation technique used 
by the company to value these assets, the third being to identify the level at which 
each company has classified their various holdings of biological assets, and the last 
being an analysis of their compliance with the disclosure requirements of IFRS 13 
applicable to the level at which they have classified their various holdings of biological 
assets. 
 
3.3  Research question  
The research question addressed by this research is: “To what extent are South 
African public companies with material holdings of biological assets complying with 
the valuation and disclosure requirements of IFRS 13 in relation to their biological 
assets?”  
To address this research question, the following analyses were undertaken: 
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 an analysis of the annual financial statements of the selected companies to 
identify whether or not they indicated that they applied IFRS 13 to their 
biological assets. This was done by checking whether the accounting policy 
notes mentioned the application of IFRS 13 to biological asset as well as 
checking the biological assets note to see if there is any mention of 
compliance with IFRS 13; 
 an analysis of the valuation techniques used for the recognition and 
measurement of these biological assets, which was done by categorising 
the valuation techniques referred to in the biological asset note according to 
the valuation techniques prescribed in IFRS 13; and 
 an analysis of the compliance of these companies’ with the disclosure 
requirements of IFRS 13 applicable to the level at which their biological 
assets were classified. This was done by creating a disclosure checklist 
based on the IFRS 13 compulsory disclosures and comparing the IFRS 13 
disclosure requirements for the level at which the companies had classified 
their various holdings of biological assets against what was actually 
disclosed in their annual financial statements. 
 
3.4  Population and sample 
The research was limited to the financial statements of JSE-listed South African public 
companies with holdings of biological assets. It is a JSE listing requirement that all 
JSE-listed companies comply fully with IFRS.  The financial statements selected were 
for the reporting periods beginning on or after 1 January 2015. Since IFRS 13 is 
applicable for reporting periods from I January 2013 and the amendments to IAS 41 
relating to bearer biological assets are applicable for reporting periods from 1 January 
2016, this research analyses financial statements compiled during the period after 
which IFRS 13 first became applicable and before the IAS 41 amendments became 
applicable. A list of JSE-listed companies was carefully scrutinised to identify 
companies with holdings of biological assets in their statements of their respective 
financial positions. Table 3.1 contains a list of the financial year ends of the nineteen 
companies that were selected for this study. 
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Table 3.1 Financial year ends of companies selected 







Source: own analysis 
 
3.5  Research method 
A content analysis of the accounting policies and biological assets notes to the 
financial statements of the selected companies was conducted. The results were 
collected and analysed using Microsoft Excel. For the purposes of this analysis, 
companies were divided into those with plants as biological assets and those with 
livestock as biological assets. A further sub-division within the category of plants was 
made between bearer plants and consumable plants, and in the category of livestock 
between bearer livestock and consumable livestock.  
Of the nineteen companies selected, it was found that thirteen had plants as biological 
assets and nine had livestock. Some companies therefore had both plants and 
livestock as biological assets and were included in both categories. Table 3.2 shows 
the number of companies found to hold the different categories of biological assets 
used in this study.  
Table 3.2 Breakdown of companies according to categories of biological assets 
Plants Livestock 
Bearer Consumable Bearer Consumable 
10 11 9 8 
Source: own analysis 
IFRS 13 requires entities to categorise assets or liabilities held at fair value into one of 
three categories in what it describes as a fair value hierarchy. IFRS 13 favours the use 
of level 1 inputs, which are quoted prices in active markets, followed by level 2 inputs, 
which are either directly or indirectly observable inputs, followed by level 3 inputs, 
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which consist of unobservable inputs (IASB, 2011). Depending on the level at which 
the assets are categorised, IFRS 13 requires different levels of disclosure.   
IFRS 13 requires all companies that measure assets or liabilities at fair value to 
disclose the fair value measurement at the end of the reporting period, as well as the 
level of the fair value hierarchy at which the fair value measurements are categorised 
(IASB, 2011). An initial analysis of the financial statements of the selected companies 
showed that most companies categorised their biological assets at level 3 of the IFRS 
13 fair value hierarchy. Where the fair value measurement method is categorised at 
level 3 of the fair value hierarchy, Table 3.3 provides a summary of the IFRS 13 
disclosure requirements. 
From the requirements listed in Table 3.3, an analysis of the financial statements was 
undertaken to ascertain whether companies with biological assets are complying with 
these requirements.  
Table 3.3 IFRS 13 level 3 disclosure requirements 
Paragraph IFRS 13 requirement 
91(a) Identification of valuation technique and inputs used 
91(b) Effect on profit or loss for the period 
93(a) Fair value at the end of the period 
93(b) Level in fair value hierarchy 
93(d) Description of valuation techniques and inputs used 
93(d) Quantitative details of significant unobservable inputs used and their impact on fair 
value 
93(e) Total gains or losses recognised in profit or loss and the line item in which those gains 
or losses are recognised 
93(e) Reconciliation of opening to closing balances showing purchases and sales 
93(f) Total gains and losses attributable to unrealised gains and losses in profit or loss 
93(g) Detailed description of valuation processes used 
 Source: IASB (2011), adapted 
Chapter 4 lays out the results of this research. 
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CHAPTER 4 
RESULTS AND DISCUSSION 
 
4.1  Introduction 
In this chapter, the analysis of the financial statements of the nineteen JSE-listed 
companies selected for this study is discussed. The study assesses whether the 
companies that are applying IAS 41 to their biological assets are also applying IFRS 
13 to the measurement and disclosure of these assets.  
IAS 41 requires companies to recognise biological assets at fair value less costs to 
sell both on initial recognition as well as at the end of each reporting period. IFRS 13 
in turn defines fair value and provides preparers of financial statements with guidance 
relating to the valuation of these assets. It also provides additional disclosure 
requirements, depending on the methods or inputs used in the valuation process. 
Out of the nineteen companies selected for this study, only one provided no indication 
of whether or not it applied IAS 41 to the valuation of its biological assets. A first step 
in this analysis was to identify which companies had indicated that they applied IFRS 
13 to the valuation of their biological assets.  
 
4.2  Application of IFRS 13 to the measurement of biological assets 
The annual financial statements of the nineteen JSE-listed companies with material 
holdings of biological assets were analysed to see which of the companies were 
applying IFRS 13 to their biological assets. It was found that only one of the listed 
companies gave no indication of whether or not it applied IFRS 13 to its biological 
assets. The remaining eighteen companies, making up 95% of those selected, 
indicated that they applied IFRS 13 to their biological assets. 
Further analysis was carried out to identify the various categories of biological assets 
held by each company and to identify the valuation techniques used by these 
companies for the valuation of their biological assets. Table 4.1 provides an indication 
of the categories of biological assets held by the selected companies.  
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Table 4.1 Number of companies with biological assets 
Categories No. 
Bearer plants 10 
Consumable plants 11 
Bearer livestock 9 
Consumable livestock 8 
Source: own analysis 
The analysis that follows uses the categories listed in Table 4.1. The results from the 
analysis are presented and structured according to these categories, where a 
percentage of companies that complied with an IFRS 13 requirement in question are 
expressed as a proportion to total number of companies within the category. The 
following section analyses the valuation techniques used by the selected companies 
in the valuation of their biological assets. 
  
4.3  Analysis of valuation techniques 
Paragraph 61 of IFRS 13 requires entities to use valuation techniques that maximise 
the use of observable inputs and minimise the use of unobservable inputs. IFRS 13 
identifies three valuation techniques that may be used to establish fair value, namely 
the market approach, the cost approach, and the income approach. These valuation 
techniques are defined as follows (IASB, 2011: paras. B5-B11): 
 The market approach uses information from transactions of similar or identical 
assets and liabilities in the market to establish fair value. 
 The cost approach uses current replacement cost to establish fair value.  
  The income approach uses discounted future cash flows to estimate current 
fair value. 
An analysis of the different valuation techniques applied by the companies to the 
measurement of their biological assets was conducted, the results of which are shown 
in Table 4.2. One of the companies used different measurement approaches to sub-
divide its bearer plant holdings, namely replacement cost for banana plants and 
deciduous and macadamia trees, and amortised cost for sugarcane roots. This 
company has been listed under the cost approach in Table 4.2. 
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Bearer plants 10% 50% 20% 20% 
Consumable plants 27% 18% 55% 0% 
Bearer livestock 67% 11% 0% 22% 
Consumable livestock 75% 12.5% 0% 12.5% 
Source: own analysis 
The first three approaches listed in Table 4.2 are fair value approaches as defined in 
IFRS 13. The last classification, amortised cost, is not a fair value measurement and 
does not form part of IFRS 13. There is no broad definition of amortised cost in any of 
the IFRS statements except for the definition relating to financial assets and financial 
liabilities in IFRS 9 and the definition of amortisation contained in IAS 38 Intangible 
Assets which defines amortisation as “the systematic allocation of the depreciable 
amount of an asset to profit or loss over its useful life” (IASB, 2010: para. 8). The 
analysis in Table 4.2 shows that amortised cost is used by certain companies to 
measure their biological assets. These companies are therefore not compliant with 
IAS 41. 
The results show that, for companies with bearer plant holdings, only 10% used the 
market approach to value these assets, while 50% used the cost approach and 20% 
used the income approach. The remaining 20% measured these assets at amortised 
cost and are therefore not fully compliant with IAS 41. 
Companies with consumable plant holdings are fully compliant with IAS 41 and IFRS 
13 in terms of the measurement of their biological assets. Of these companies, 27% 
used the market approach, 18% used the cost approach and 55% used the income 
approach.  
The analysis found further that 22% of companies with bearer livestock holdings were 
non-compliant, electing to measure their biological assets at amortised cost, while 
67% indicated that they measured their biological assets using the market approach 
and 11% used the cost approach. 
The majority of companies with consumable livestock holdings measured their 
biological assets by using the market approach, with 75% using this method. Of the 
balance, 12.5% used the cost approach and 12.5% used amortised cost.   
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It is clear from these results that companies with different categories of biological 
assets use different valuation techniques. While there is very little consistency across 
the different categories, there is relative consistency within each category. It may still 
be, however, that each company is using the approach that it finds the most practical, 
regardless of what is seen as the best measure within the industry sector in question. 
 
4.4  IFRS 13 fair value measurement disclosure requirements 
Using the steps described in section 3.2, a further analysis was carried out on the 
compliance of the selected companies with the IFRS 13 disclosure requirements. The 
results of this analysis are shown in Tables 4.3 and 4.4. 
Table 4.3 IFRS 13 disclosures by companies with plant holdings 
Paragraph IFRS 13 requirement Bearer Consumable 
91(a) Identification of valuation technique and inputs used 100% 100% 
91(b) Effect on profit or loss for the period 80% 100%  
93(a) Fair value at the end of the period 80% 100% 
93(b) Level in fair value hierarchy 80% 100% 
93(d) Description of valuation techniques and inputs used 80% 100% 
93(d) Quantitative details of significant unobservable inputs 
used and their impact on fair value 40% 55% 
93(e) Total gains or losses recognised in profit or loss and the 
line item in which those gains or losses are recognised 50% 73% 
93(e) Reconciliation of opening to closing balances showing 
purchases and sales 80% 100% 
93(f) Total gains and losses attributable to unrealised gains 
and losses in profit or loss 0% 0% 
93(g) Detailed description of valuation processes used 10% 9% 
Source: own analysis 
As seen in Table 4.3, all of the companies with bearer and consumable plants 
identified the valuation techniques used to measure these assets. While 80% of 
companies with bearer plant holdings provide five of the ten compulsory disclosures 
required by IFRS 13. In relation to the other IFRS 13 disclosure requirements, 50% of 
the companies disclosed total gains or losses recognised in profit or loss and the line 
item in which those gains or losses are recognised, 40% disclosed quantitative details 
of significant unobservable inputs used and their impact on fair value, 10% provided a 
description of the valuation process in detail and none of the companies with bearer 
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plants disclosed the total gains and losses attributable to unrealised gains and losses 
in profit or loss.  The remaining 20% of the companies with bearer plant holdings did 
not comply with nine of the ten IFRS 13 disclosure requirements. This is because they 
used amortised cost, which is not a measure of fair value.  
All of companies with consumable plant holdings were fully compliant with 60% of the 
disclosure requirements of IFRS 13. The three disclosures with which such companies 
were less compliant were those relating to the total gains or losses recognised in profit 
or loss and the line item in which those gains or losses are recognised, which had a 
73% compliance, the quantitative details of significant unobservable inputs used and 
their impact on fair value had 55% compliance and detailed description of valuation 
processes used which only one company with consumable plant holdings was 
compliant. Same as companies with bearer plants, none of the companies with 
consumable plants disclosed the total gains and losses attributable to unrealised gains 
and losses in profit or loss. 
Table 4.4 IFRS 13 disclosures by companies with livestock holdings 
Paragraph IFRS 13 requirement Bearer Consumable 
91(a) Identification of valuation technique and inputs used 89% 88% 
91(b) Effect on profit or loss for the period 78% 88% 
93(a) Fair value at the end of the period 78% 88% 
93(b) Level in fair value hierarchy 78% 88% 
93(d) Description of valuation techniques and inputs used 78% 88% 
93(d) Quantitative details of significant unobservable inputs 
used and their impact on fair value 56% 63% 
93(e) Total gains and losses in profit or loss per line item 78% 88% 
93(e) Reconciliation of opening to closing balances showing 
purchases and sales 78% 88% 
93(f) Total gains and losses attributable to unrealised gains 
and losses in profit or loss 11% 13% 
93(g) Detailed description of valuation processes used 11% 13% 
Source: own analysis 
As seen in Table 4.4, Only one company of the companies with bearer livestock that 
that could not identify the valuation technique and inputs used, while 78% of companies with 
bearer livestock holdings disclosed six of the ten disclosures required by IFRS 13. The 
three disclosures with which these companies were less compliant were those relating 
to the quantitative details of significant unobservable inputs used and their impact on fair value, which 
had a 56% compliance, and those relating to total gains and losses attributable to unrealised 
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gains and losses in profit or loss and a detailed description of valuation processes used, with which 
only one company with bearer livestock holdings was compliant. The remaining 22% 
of the companies with such holdings did not comply with any of the IFRS 13 disclosure 
requirements. These companies also used amortised cost for their bearer livestock, 
which is not a measure of fair value. 
Of the companies with consumable livestock holdings, 88% disclosed seven of the 
minimum disclosures required by IFRS 13. The three disclosures with which 
companies with consumable livestock holdings were less compliant were those 
relating to the quantitative details of significant unobservable inputs used and their impact on fair 
value, which had 63% compliance and only one company of those with consumable 
livestock disclosed total gains and losses attributable to unrealised gains and losses in profit or loss 
and detailed description of valuation processes used 
These results show that most of the nineteen JSE-listed companies selected for this 
study complied with most of the disclosure requirements of IFRS 13, and that the only 
ones that were completely non-compliant with the disclosure requirements were not 
using a fair value measurement for their biological assets and are therefore compliant 
with neither IAS 41 nor IFRS 13. The one disclosure with which 90% of the companies 
were non-compliant relates to providing a detailed description of the valuation process 
used in arriving at the level 3 valuations of their biological assets. 
 
4.5  Conclusion 
This chapter has discussed the results of the research conducted on the annual 
financial statements of the nineteen JSE-listed companies selected for this study. The 
purpose of this research was to assess the extent to which these companies applied 
IFRS 13 to their biological assets, as well as the extent of these companies’ 
compliance with the disclosure requirements of IFRS 13 in their annual financial 
statements. 
Of these nineteen companies, six used amortised cost to value at least one category 
of biological assets. Three companies used amortised cost to value their bearer plant 
holdings, two used amortised cost to value their bearer livestock holdings, and one 
used amortised cost to value its consumable livestock holdings. In contrast, all 
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companies with consumable plant holdings used one of the fair value measures 
contained in IFRS 13 to value these assets.  
The majority of companies with bearer plant holdings used a replacement cost 
approach for the valuation of their holdings, while the majority of companies with 
consumable plant holdings used an income approach to measure these assets. 
However, three companies still used amortised cost to measure their bearer plant 
holdings, while none of the companies used amortised cost to measure its consumable 
plant holdings. As long as companies in the same industry continue to use different 
valuation techniques to measure the fair value of their holdings, a comparison of 
companies for decision-making purposes will remain difficult.  
There is greater consistency among companies with livestock holdings, with the 
majority of companies with both bearer and consumable livestock holdings using a 
market approach to value these assets. However, two companies still used amortised 
cost, one to measure its bearer livestock holdings only and the other to measure both 
bearer and consumable livestock holdings. Comparison among companies with 
livestock holdings for decision-making purposes is therefore more reliable than among 
companies with plant holdings.  
In terms of the IFRS 13 minimum disclosure requirements, all of the companies that 
used one of the methods for assessing fair value advocated in IFRS 13 complied with 
the majority of the standard’s disclosure requirements. Disappointingly, only 10% of 
companies with bearer plant holdings, 9% of companies with consumable plant 
holdings, 11% of companies with bearer livestock holdings, and 13% of companies 
with consumable livestock holdings complied with the IFRS 13 disclosure requirement 
to provide a detailed description of the valuation process applied to arrive at the level 
3 valuation used.  
The discussion in this chapter has shown that the JSE-listed companies with material 
holdings of biological assets selected for this study are, with a few exceptions, applying 
IFRS 13 to their biological assets and are compliant with most of the standard’s 
disclosure requirements. The conclusion, which follows, will discuss the extent to 
which the application of IFRS 13 has addressed the themes of relevance, faithful 
representation, comparability and standardisation of disclosure identified in the 
literature review in Chapter 2. 





5.1  Introduction  
As stated in Chapter 1, the IASB issued IFRS 13 in May 2011 to provide further 
guidance on how to apply fair value measurement in the preparation of annual financial 
statements. IFRS 13 encourages the use of observable inputs with the aim of reducing 
fair value measurement variability and subjectivity. It favours the use of level 1 inputs, 
which are quoted prices in active markets; followed by level 2 inputs, which are either 
directly or indirectly observable inputs; followed lastly by level 3 inputs, which consist 
of unobservable inputs. 
IAS 41 requires entities with biological assets to measure both their biological assets 
and their agricultural produce at fair value on initial recognition and at the end of each 
financial reporting period. Therefore, with effect from 1 January 2013, all entities 
holding biological assets are required to apply IFRS 13 to the measurement of these 
assets. 
The objective of this study was, firstly, to assess whether South African JSE-listed 
companies with material holdings of biological assets were applying IFRS 13 to the 
valuation and measurement of their biological assets, secondly, to determine the 
valuation technique that they were applying to these assets and, thirdly, to further 
assess the compliance of these companies with the minimum disclosure requirements 
in IFRS 13 for the level at which they classified their biological assets in terms of the 
IFRS 13 fair value hierarchy. 
This concluding chapter summarises the findings of the literature review before 
continuing to look at the research methodology applied in the study and the resulting 
findings. The chapter concludes by indicating the limitations of this study and 
suggesting areas for further research. 
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5.2  Literature review  
The literature review in Chapter 2 reviewed prior research relating to both the financial 
reporting of biological assets and issues around fair value reporting. The literature was 
analysed to specifically determine the extent to which prior research reported on the 
qualitative characteristics of relevance and faithful representation as they relate to the 
disclosure of biological assets and the measurement of certain assets at fair value. It 
also discussed the themes of comparability in relation to financial reporting and the 
standardisation of disclosure. It was found that most authors came to the conclusion 
that fair value is more value-relevant and reliable when compared to historical cost, 
especially for consumable biological assets 
Authors also raised concerns that fair value measurement has the potential to impair 
the faithful representation of financial information, especially at IFRS 13 levels 2 and 
3, because managers now have an opportunity to manipulate financial statements by 
choosing to use fair value measurement in a way that will work in their favour for those 
assets that are not traded in an active market. This may not be in the best interests of 
all stakeholders. Users will have more confidence in a company’s financial statements 
if they are assured that the company’s financial information is relevant and faithfully 
presented.  
In relation to biological asset holdings, companies should ensure that they consider all 
factors affecting the biological asset in question in determining its fair value. Increased 
disclosure of the valuation methods used will achieve value relevance for many 
different types of biological assets, particularly those, like forests and plantations that 
require several inputs in order to arrive at a fair value. Companies with biological 
assets will need to attain a balance between over-disclosure and under-disclosure. 
This balance can be achieved by disclosing more technical information about 
biological assets if market values are not available. More frequent valuation 
calculations may also make it easier for companies to produce standardised 
information that is both relevant and faithfully represented. 
Increased standardisation of disclosure is a pre-requisite for increased comparability 
between entities within the same industry sector. Faithful representation is enhanced 
when financial information is comparable and disclosed in a standardised way. It is 
hoped that IFRS 13, with its increased emphasis on the use of market-based 
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valuations, combined with greater disclosure requirements when other valuation 
methods are used, will lead to increased standardisation of disclosure. However, there 
is a concern that disclosing too much information will not always be value-relevant, 
and it is hoped that standardised disclosure can be achieved through the use of 
minimal but relevant information.  
 
5.3  Research methodology  
A content analysis of the financial statements of the nineteen South African JSE-listed 
companies with biological asset holdings was undertaken to assess whether they 
applied IAS 41 and IFRS 13 to their biological assets and, if they did, the extent of 
their compliance with the minimum disclosure requirements listed in IFRS 13. 
The accounting policy notes to the financial statements of each company were 
analysed to determine whether they indicated that the company had applied IFRS 13 
requirements to the valuation of its biological assets. The biological assets note to the 
financial statements for each company was then analysed to determine the valuation 
technique used for the valuation of its biological assets. In addition to the three 
valuation techniques indicated in IFRS 13 paragraph 62, namely the market approach, 
cost approach and income approach, companies were also found to be applying 
amortised cost to certain biological assets. For the purposes of this analysis, the 
biological assets held by each company were divided into four categories, namely 
bearer plants, consumable plants, bearer livestock, and consumable livestock. 
Because all the companies that were applying an IFRS 13 fair valuation technique 
indicated that they were using level 3 inputs to value their biological assets, the IFRS 
13 level 3 disclosure requirements were listed and checked against the annual 
financial statements of the nineteen selected companies in order to assess the extent 
of their compliance with these disclosure requirements. 
The financial statements that were analysed were the first set of annual financial 
statements for the financial reporting periods beginning on or after 1 January 2015. 
In this concluding chapter, the result and discussion section will be discussing the 
results in summary and will also be discussing the interpretation and implication of the 
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results. Further on the discussion of the results, a deeper interpretation will be 
discussed in relation to the conceptual framework’s qualitative characteristics of 
relevance, faithful representation, comparability, and standardisation of disclosure, 
specifically in relation to the usefulness of the financial information of agricultural 
entities. 
 
5.4  Results and discussion 
Chapter 4 of this dissertation presents the results of this study and the discussion of 
these results.  
Figure 5.1 Summary of finding: Valuation techniques 
 
Source: own analysis 
Figure 5.1 shows the different valuation techniques applied by the companies to their 
biological assets. It can be seen that, for companies with bearer plant holdings, 10% 
used a market approach, 50% used replacement cost, 20% used an income approach 
and the remaining 20% measured their biological assets at amortised cost.  
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This shows that 80% of companies with bearer plants have used a valuation technique 
prescribed by IFRS 13 which has made the values in the financial statements more 
future predictive and more confirmatory of the past prediction, as a result improving 
the relevance of the financial information presented by agricultural entities. This has 
also improved comparability. 
Seeing that 50% of companies used the same approach (replacement cost), this has 
improved the understandability of financial statements which results in improved 
standardisation of disclosure. Further to that, when different companies use the same 
valuation technique it becomes easy for the users the compare the financial 
performance and position of those companies, thus being able to make informed 
decision about the companies. 
For companies with consumable plant holdings as shown in Figure 5.1, all companies 
applied a fair value approach, with 27% using a market approach, 19% using the cost 
approach and 55% using an income approach. The financial information of these 
companies is highly relevant because all of them have used fair value approaches 
which produces high degree of predictive and confirmatory value. Without a doubt 
these companies financial statements have a high degree of comparability because 
users will find it easier to compare financial information which was produced using 
prescribed and known valuation techniques.  
For companies with bearer livestock holdings, Figure 5.1 reveals that 67% used a 
market approach, 11% used the cost approach and the remaining 22% measured their 
biological assets at amortised cost. The majority of companies with bearer livestock 
use the same approach (market approach), this has improved the understandability of 
financial statements which results in improved standardisation of disclosure. The use 
of the same valuation technique by the majority of companies in this category makes 
it easier for users to compare the financial performance and position of these 
companies, which enables users to make informed decisions. 
For companies with consumable livestock holdings, as seen in Figure 5.1, 74% used 
a market approach, 13% used the cost approach and the remaining 13% measured 
their biological assets at amortised cost. The financial information of these companies 
is highly relevant because almost all of them have used market approach which 
produces a high degree of predictive and confirmatory value. These financial 
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statements also have high degree of comparability because users will find it easier to 
compare financial information which was produced using the same approach which is 
prescribed and known.  
These results indicate that, while there is little consistency across the different 
categories of biological assets, there is significant consistency within each category. 
In turn, this consistency enhances greater adherence to the conceptual framework’s 
qualitative characteristics of relevant and faithful representation of financial 
information. As a result, it contributes to the usefulness of the annual financial 
statements on the companies with material holdings of biological assets.  
Figure 5.2 Summary of findings: Disclosure 
 
Source: own analysis 
In terms of the disclosure requirements of IFRS 13, Figure 5.2 shows that 80% of the 
companies with bearer plant holdings provided users of their financial statements with 
five of the ten IFRS 13 level 3 disclosure requirements. Surprisingly, only one company 
provided all the required disclosures, including a detailed description of the valuation 
process it used. In relation to the useful financial information, more that 50% of 
company’s bearer plants complied with seven of the ten IFRS 13 disclosure 
requirements which shows, with space for improvement, a good adherence to 
standardisation of disclosure because more disclosure makes information more 
understandable and which will also make financial statements more comparable 
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because companies has disclosed enough information to compare their results fairly. 
In the future this increased consistency should enhance faithful presentation with an 
emphasis on completeness because companies are currently still less descriptive in 
their disclosures. 
Similarly, as seen in Figure 5.1, 100% of the companies with consumable plant 
holdings provided users with six of the ten IFRS 13 level 3 disclosure requirements, 
while only one company provided all the required disclosures, including a detailed 
description of the valuation process used. This shows a good adherence to 
standardisation of disclosure because more disclosure makes information more 
understandable and which will also make financial statements more comparable 
because companies has disclosed enough information to compare their results fairly. 
In the future this increased consistency should enhance faithful presentation with an 
emphasis on completeness because companies are currently still less descriptive in 
their disclosures. 
It is worth noting that companies with both bearer and consumable plants could have 
compromised relevance and faithful presentation by non-disclosure of total gains and 
losses attributable to unrealised gains and losses in profit or loss, while only one 
company disclosed a detailed description of the valuation processes used. 
Figure 5.2 shows that the results from companies with bearer livestock holdings were 
similar to that of companies with bearer and consumable plant holdings, with 78% 
providing users of their financial statements with six of the ten IFRS 13 level 3 
disclosure requirements and only one company providing all the disclosures in any 
detail, including a description of the valuation process used in any detail. In relation to 
the useful financial information, more than 50% of company’s with bearer livestock 
complied with eight of the ten IFRS 13 disclosure requirements which shows, with 
space for improvement, a solid adherence to standardisation of disclosure because 
more disclosure makes information more understandable and which will also make 
financial statements more comparable because companies have disclosed enough 
information to compare their results fairly. In the future this increased consistency 
should enhance faithful presentation with an emphasis on completeness because 
companies are currently still less descriptive in their disclosures. 
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Companies with consumable livestock holdings reflected a similar disclosure pattern, 
as evidenced in Figure 5.2 that 88% are providing financial statement users with five 
of the ten IFRS 13 level 3 disclosure requirements and only one company providing 
all the disclosures, including a detailed description of the valuation process it used. 
More than 63% of companies with consumable livestock complied with eight of the ten 
IFRS 13 disclosure requirements, which shows a solid adherence to standardisation 
of disclosure because more disclosure makes information more understandable and 
which will also make financial statements more comparable because companies has 
disclosed enough information to compare their results fairly. In the future this 
increased consistency should enhance faithful presentation with an emphasis on 
completeness because companies are currently still less descriptive in their 
disclosures. 
Similar to companies with plants as biological assets, most companies with both 
bearer and consumable livestock could have compromised relevance and faithful 
presentation by non-disclosure of both total gains and losses attributable to unrealised 
gains and losses in profit or loss and a detailed description of valuation processes 
used. 
The above results are in line with the findings of Filip, Hammami, Huang, Jeny, 
Magnan and Moldovan (2017), discussed in Chapter 2, and indicates that the 
application of IFRS 13 has improved the comparability and standardisation of 
disclosure of financial statements, which predominantly benefits investors and 
analysts.  
Only one of the companies with both bearer and consumable plant holdings managed 
to comply with all the disclosure requirements in IFRS 13. While most of the remaining 
companies appear to have gone to great lengths to comply with as many of the IFRS 
13 disclosure requirements as possible, it seems that more research is needed to 
determine why most companies are struggling to be fully compliant, especially 
because the financial reporting period studied was not the first to which IFRS 13 
applied. Companies with biological assets need to consider putting systems in place 
that will enable them to produce both quantitative and qualitative data on the 
unobservable inputs used to value their biological assets, and to document the 
valuation processes in greater detail. That will also improve the usefulness of financial 
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information in the agricultural sector. As stated in the conceptual framework, financial 
information is more useful the more relevant, faithfully presented, comparable and 
understandable it is.  
 
5.5  Limitations 
This study is limited to companies listed on the JSE. There are companies with 
material holdings of biological assets that are not listed on the JSE but are still required 
by the Companies Act (South Africa, 2008) to prepare IFRS-compliant financial 
statements. Due to time constraints, these companies do not form part of the present 
research, because their annual financial statements are not easily accessible or are 
unavailable. 
This dissertation looks at financial statements prior to the amendments to IAS 41 that 
removed bearer plant holdings from the scope of IAS 41 and required them to be 
accounted for according to IAS 16. It therefore does not take these amendments into 
account. 
 
5.6  Areas for further research  
There are a number of areas for possible further research on the issues identified in 
this dissertation. A qualitative analysis in the form of interviews with those who prepare 
financial statements in order to determine their views on the usefulness of fair value in 
relation to biological assets would be informative. It would also be beneficial to 
determine if they find complying with the disclosure requirements of IFRS 13 onerous 
or not. 
Research involving questionnaires and interviews with the users of financial 
statements would help to determine whether or not they prefer the application of fair 
value to historical cost in relation to the valuation of biological assets. It may also be 
helpful to determine whether such users find the additional IFRS 13 disclosure 
requirements to be advantageous or not. 
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In terms of the period since the removal of bearer plant holdings from the scope of IAS 
41 in June 2014, which is applicable to financial statements with reporting periods 
starting on or after 1 January 2016, further research on the measurement, presentation 
and disclosure of these assets may be useful.  
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